Two patients walk in the same week with what looks, on the scale, like the same problem. The first is a 52-year-old man, BMI 31, waist circumference 42 inches, with a hard, protruding abdomen that is firm to the touch when he sits down. The second is a 48-year-old woman, BMI also 31, who carries her weight on her hips and thighs with a softer, pinchable abdominal layer. Same BMI. Two completely different metabolic risk profiles. The first patient's labs come back with fasting insulin of 22, triglycerides of 240, fatty liver on his last ultrasound, and an HbA1c of 6.1. The second patient's labs are unremarkable.
This is the difference between visceral fat and subcutaneous fat, and it is one of the most clinically important distinctions in the entire weight management conversation. The scale does not see it. BMI does not see it. The patient feels the same number of pounds either way. But from the standpoint of cardiometabolic risk, these are not the same condition.
I spent seventeen years in emergency medicine, the cardiac ICU, and the cath lab before opening this practice. The patients we wheeled into the cath lab at three in the morning with chest pain were rarely the soft, pinchable patients. They were almost always the patients with hard, central, visceral adiposity. That pattern is not coincidence. It is physiology, and it shapes how I think about the medical weight loss program here.
What visceral fat actually is — and why it behaves like a separate organ
Subcutaneous fat is the layer just under the skin. It is what you can pinch. Its primary function is energy storage and thermoregulation, and from a metabolic standpoint, it is largely inert. People can carry significant subcutaneous fat and have fasting insulin, lipids, and inflammatory markers in the optimal range. It is not aesthetically what most patients want, but it is not driving their cardiovascular risk in the same way.
Visceral fat is different. It sits inside the abdominal cavity, wrapped around the liver, pancreas, intestines, and the mesentery. It is metabolically active in a way subcutaneous fat is not. Visceral adipocytes secrete inflammatory cytokines — TNF-alpha, IL-6, resistin — directly into the portal circulation. That portal venous drainage hits the liver first, which is why visceral adiposity correlates so tightly with hepatic insulin resistance and non-alcoholic fatty liver disease.
The cytokines that visceral fat releases drive systemic insulin resistance, suppress adiponectin (which is protective), promote endothelial dysfunction, and accelerate atherogenesis. This is why two patients at the same BMI can have wildly different cardiovascular risk profiles. The visceral fat is not just stored calories. It is an active endocrine organ that is producing inflammation at the source.
Belly fat types matter clinically because they have different mechanisms and respond to different interventions. The hard, protruding abdomen with a thin pinchable layer is mostly visceral. The soft abdomen with a clear waist-to-hip differential is mostly subcutaneous. The mixed pattern is common in mid-life, particularly in women after menopause when estrogen withdrawal shifts fat distribution toward the abdomen.
How I measure it — and what the numbers mean
The simplest in-office screen is waist circumference. Measured at the level of the umbilicus, after a normal exhale, with a non-stretch tape. The clinically meaningful thresholds: above 40 inches in men, above 35 inches in women. Above those numbers, visceral adiposity is statistically likely and the metabolic risk profile shifts.
Waist-to-hip ratio adds nuance. Above 0.90 in men or 0.85 in women suggests an android (visceral) distribution. Below those numbers suggests a gynoid (subcutaneous) distribution. The android pattern carries the cardiometabolic risk.
For patients where the picture is ambiguous or where I want a precise baseline to track against, DEXA body composition is the standard. It separates lean mass, subcutaneous fat, and visceral adipose tissue (VAT) by mass and percentage. A VAT mass above 100 cm² in women or 130 cm² in men is the threshold I take seriously. We use DEXA selectively in the practice — not on every patient, but for patients where the numbers will change the management plan.
The labs that confirm the visceral pattern: fasting insulin (above 10 µIU/mL is a flag, above 15 is unequivocal insulin resistance), HOMA-IR calculated from fasting insulin and glucose, triglyceride-to-HDL ratio (above 3.5 in white patients and above 2.0 in Black patients suggests insulin resistance), HbA1c, and hs-CRP for the inflammatory load. ALT elevation suggests hepatic involvement. These are the markers I want before we start titrating any intervention.
Why GLP-1 medications work disproportionately well on visceral fat
This is one of the more useful clinical observations from the GLP-1 literature. Semaglutide and tirzepatide do not just produce weight loss — they preferentially reduce visceral adipose tissue. Multiple imaging studies have shown that the percentage reduction in VAT exceeds the percentage reduction in total body fat. The mechanism is partly the improvement in insulin signaling, partly direct effects on hepatic fat, and partly the metabolic shift that follows from reduced caloric intake in someone who was previously in a hyperinsulinemic state.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
For the patient with the hard, protruding abdomen and the elevated insulin, GLP-1 therapy is often the right primary intervention. The visceral compartment responds, the inflammatory markers come down, the lipid panel improves, and the cardiovascular risk profile shifts in a measurable way. I see HbA1c drop, triglycerides drop, ALT normalize, and waist circumference decrease over the first three to six months in patients who tolerate the medication and engage with the protocol.
For the patient with primarily subcutaneous fat and a normal metabolic panel, the calculus is different. GLP-1 will still produce weight loss, but the clinical justification is weaker. I am more cautious about using a medication that requires long-term commitment when the underlying metabolic disease is not the driver.
What I look for at the workup
When I evaluate someone for the medical weight loss program, I am not just asking about weight. I am asking what kind of fat we are dealing with, what is driving it, and what is going to move the needle. The history I take covers prior weight loss attempts and why they failed, current sleep quality (sleep restriction drives visceral fat accumulation independent of caloric intake), stress patterns and cortisol load, alcohol intake (alcohol preferentially drives hepatic and visceral fat), and current activity pattern with attention to resistance training versus cardio alone.
The labs I order include the metabolic markers above, a full thyroid panel because subclinical hypothyroidism contributes to visceral fat accumulation, the sex hormone panel because both estrogen withdrawal in women and low testosterone in men drive central adiposity, and the inflammatory markers. For some patients I add a four-point salivary cortisol to evaluate the diurnal pattern.
The treatment plan that comes out of this is rarely just a GLP-1 prescription. For the man with low testosterone driving his abdominal pattern, hormone optimization — in his case, men's TRT — is part of the picture because addressing the hormonal driver makes the GLP-1 more effective. For the perimenopausal woman whose visceral fat showed up in the two years after her cycles became irregular, addressing the estrogen and progesterone shifts is part of the plan. For the patient whose sleep has been broken for years, we are not going to fix the visceral fat without fixing the sleep.
Why this matters for cardiovascular risk
This is the part that draws on what I saw for seventeen years before this practice. The patients who came into the cath lab in their fifties and sixties were not always the heaviest patients. They were the ones with the metabolic syndrome pattern — visceral adiposity, insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. The classic central obesity pattern. By the time we were threading a wire through their coronary arteries, the disease had been brewing for fifteen or twenty years.
If I can intervene on the visceral compartment in someone in their forties or early fifties — drop the inflammatory load, restore insulin sensitivity, normalize the lipid pattern — the trajectory bends. Not theoretically. Measurably. The cardiovascular outcome trials on GLP-1 medications and on hormone optimization in deficient patients show real reductions in major adverse cardiovascular events. The visceral fat reduction is part of the mechanism by which that happens.
This is the framework I am working from when I sit across from a patient with a 42-inch waist and a fasting insulin of 22. The conversation is not about looking better in a swimsuit. It is about whether we are going to be looking at coronary disease in fifteen years that did not have to happen.
Where [nutritional counseling](/services/nutritional-counseling) and resistance training fit
Medication does not work in isolation. The patients who get the best long-term results are the ones who pair the metabolic intervention with a dietary pattern that does not re-feed the visceral compartment. That generally means lower carbohydrate density, prioritized protein at every meal, and meaningful elimination of liquid calories and processed snack foods. The exact pattern is individual and we work it out at the nutritional counseling sessions, but the goal is consistent: lower the insulin signaling pressure on the system over the long term.
Resistance training matters more than most patients realize. Visceral fat reduction without preservation of lean mass produces a worse metabolic outcome — the patient is lighter but their resting metabolic rate has dropped, and the visceral compartment is more likely to refill when the medication is reduced. Two to three sessions of resistance training per week, focused on compound movements, is the floor. We talk about this at every reassessment because it is the variable that most often determines whether the loss holds.
The next step if this sounds like your picture
If you are recognizing yourself in the visceral pattern — the hard central abdomen, the labs that have been creeping in the wrong direction, the family history of cardiovascular disease, the weight that has not responded to the same approaches that worked in your thirties — the useful next step is a weight loss assessment to organize your picture, followed by a comprehensive consultation. Bring any prior labs you have, including ones you may have been told were "normal." The trend matters more than any single value, and the assessment looks at the trend.
Both the Columbus clinic and the Warner Robins clinic run the medical weight loss program with the same protocols. Online booking is open through the JaneApp portal. At the first visit we will walk through your history, examine the actual fat distribution rather than just the scale number, order the labs we need, and at the second visit we will sit down with the data and build a plan that targets the specific compartment that is driving your risk.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.